| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Agouron Pharmaceuticals |
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002170 |
Purpose
The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.
| Condition | Intervention | Phase |
|
Mycobacterium Avium-Intracellulare Infection HIV Infections |
Drug: Nelfinavir mesylate |
Phase II |
| MedlinePlus related topics: | AIDS |
| Drug Information available for: | Nelfinavir Nelfinavir Mesylate |
| Study Type: | Interventional |
| Study Design: | Treatment, Placebo Control, Safety Study |
| Official Title: | A Pilot, Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Disseminated Mycobacterium Avium Complex Disease (MAC) in AIDS Patients Who Are Receiving Standard Acute Treatment for This Opportunistic Infection |
Eligibility
| Ages Eligible for Study: | 13 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have:
Prior Medication:
Allowed:
Patients no more than 7 days of therapy for MAC disease.
Exclusion Criteria
Prior Medication:
Excluded:
Prior therapy (or less than 2 weeks) with protease inhibitors other than saquinavir.
Contacts and Locations| United States, California | |||||
| Harbor UCLA Med Ctr | |||||
| Torrance, California, United States, 90502 | |||||
| Univ of California / San Diego Treatment Ctr | |||||
| San Diego, California, United States, 92103 | |||||
| United States, Illinois | |||||
| Rush Presbyterian - Saint Luke's Med Ctr | |||||
| Chicago, Illinois, United States, 60612 | |||||
| United States, Massachusetts | |||||
| Boston VA Med Ctr / 151 | |||||
| Boston, Massachusetts, United States, 02730 | |||||
| United States, Texas | |||||
| Baylor Univ | |||||
| Houston, Texas, United States, 77009 | |||||
| Agouron Pharmaceuticals |
More Information
| Study ID Numbers: | 259C, Study 518, AG1343-518 |
| First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002170 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|
|
